Advertisement

St. Jude Medical touts clinical findings in support of its Genesis peripheral nerve stimulation implant in helping patients with chronic migraines.

St. Jude Medical logo

Medical device giant St. Jude Medical (NYSE:STJ) announced new clinical results for its migraine-management implants, reporting significant relief for patients who, on average, spend more days with migraines than without.

At 12 weeks of follow-up, St. Jude provided pain relief in 42% of the patients, with 53% ranking that relief as "excellent" or "good," according to a press release.

Advertisement
Advertisement